Xia Yihua, Han Kangning, Cheng Yujing, Wang Zhijian, Gao Fei, Ma Xiaoteng, Zhou Yujie
Beijing Institute of Heart Lung and Blood Vessel Disease, 100029 Beijing, China.
Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, 100029 Beijing, China.
Rev Cardiovasc Med. 2023 Nov 24;24(11):332. doi: 10.31083/j.rcm2411332. eCollection 2023 Nov.
Peripheral artery disease (PAD) elevates the risk of adverse outcomes. The current work aimed to evaluate the influence of PAD in acute coronary syndrome (ACS) cases administered percutaneous coronary intervention (PCI), and to determine whether PAD adds incremental prognostic value to the global registry of acute coronary events (GRACE) scale.
To retrospectively analyze a single-center, prospective cohort trial, we consecutively included ACS cases administered PCI. Individuals with and without PAD were comparatively examined for clinical outcomes. The primary endpoint was major adverse cardiovascular events (MACEs), a compound item encompassing all-cause death, myocardial infarction (MI), stroke and repeat revascularization. The added value of PAD based on a reference model was examined.
PAD was detected in 179 (10.4%) of the 1,770 included patients. The incidence rates of MACEs (40.3% vs. 17.9%), all-cause death (11.2% vs. 1.6%), cardiovascular death (8.9% vs. 1.4%), MI (8.4% vs. 2.2%) and repeat revascularization (30.2% vs. 15.2%) were all markedly elevated in PAD cases in comparison with the non-PAD group ( 0.001). After adjusting for other confounding variates, PAD independently predicted MACE occurrence (hazard ratio = 1.735, 95% confidence interval: 1.281-2.351). Addition of PAD resulted in remarkably increased predictive performance for MACE compared to the baseline GRACE score (Harrell's C-statistic: 0.610 vs. 0.587, 0.001; net reclassification improvement: 0.134, 0.001; integrated discrimination improvement: 0.035, 0.001).
In ACS cases administered PCI, PAD independently worsens clinical outcomes and adds incremental value to the GRACE risk score.
外周动脉疾病(PAD)会增加不良后果的风险。当前研究旨在评估PAD对接受经皮冠状动脉介入治疗(PCI)的急性冠状动脉综合征(ACS)患者的影响,并确定PAD是否能为急性冠状动脉事件全球注册(GRACE)量表增加额外的预后价值。
为回顾性分析一项单中心前瞻性队列试验,我们连续纳入接受PCI的ACS患者。对有和没有PAD的个体的临床结局进行比较研究。主要终点是主要不良心血管事件(MACE),这是一个综合指标,包括全因死亡、心肌梗死(MI)、中风和再次血管重建。研究了基于参考模型的PAD的增加值。
在纳入的1770例患者中,179例(10.4%)检测到PAD。与非PAD组相比,PAD患者的MACE发生率(40.3%对17.9%)、全因死亡(11.2%对1.6%)、心血管死亡(8.9%对1.4%)、MI(8.4%对2.2%)和再次血管重建(30.2%对15.2%)均显著升高(P<0.001)。在调整其他混杂变量后,PAD独立预测MACE的发生(风险比=1.735,95%置信区间:1.281 - 2.351)。与基线GRACE评分相比,加入PAD后MACE的预测性能显著提高(Harrell's C统计量:0.610对0.587,P<0.001;净重新分类改善:0.134,P<0.001;综合鉴别改善:0.035,P<0.001)。
在接受PCI的ACS患者中,PAD独立地恶化临床结局,并为GRACE风险评分增加额外价值。